Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186709 | 0.87 | HPGD (0.48) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL1186705 | 0.87 | HPGD (0.48) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL12873541 | 0.87 | HPGD (0.48) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL1576006 | 0.84 | HPGD (0.50) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL21997258 | 0.82 | HPGD (0.49) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL1773494 | 0.82 | HPGD (0.47) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL1773493 | 0.82 | HPGD (0.47) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL22907013 | 0.82 | HPGD (0.47) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL1773571 | 0.82 | HPGD (0.47) | HPGDRECQLKDM4EPKMGPR119 | |
| SCHEMBL310405 | 0.82 | HPGD (0.54) | HPGDRECQLKDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | RNASE1, PKD1, GPR6 | HPGD 2915/4885RECQL 4260/4885KDM4E 2358/4885 |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | RNASE1, PKD1, GPR6 | HPGD 3004/4885RECQL 4374/4885KDM4E 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.